Literature DB >> 16061558

Phenotype variability of neural crest derived tumours in six Italian families segregating the same founder SDHD mutation Q109X.

L Simi1, R Sestini, P Ferruzzi, M S Gaglianò, F Gensini, M Mascalchi, L Guerrini, C Pratesi, P Pinzani, G Nesi, T Ercolino, M Genuardi, M Mannelli.   

Abstract

BACKGROUND: Mutations in genes coding for the mitochondrial complex II succinate dehydrogenase (SDH) subunits cause familial neural crest derived (NCD) tumours.
METHODS: Index cases from six apparently unrelated families affected by NCD tumours were analysed for mutations in the SDHB, SDHC, and SDHD genes.
RESULTS: The same nonsense germline heterozygous mutation (Q109X) in exon 4 of the SDHD gene was found in each of the six families. Overall, 43 heterozygotes were identified. These were evaluated for the presence of NCD tumours through radiological examination of the neck, thorax, and abdomen, and measurement of urinary metanephrines and plasma chromogranin A. A novel missense SDHD variant, T112I, which did not segregate with the Q109X mutation and was not associated with phenotypic manifestations, was observed in one of the families. Microsatellite analysis showed a common haplotype in all individuals heterozygous for the Q109X mutation, indicating a founder effect. Overall, 18 heterozygotes were clinically affected by at least one NCD tumour. Every affected patient inherited the germline mutation from the father, confirming SDHD maternal genomic imprinting. Penetrance of the paternally inherited mutation progressively increased from 33% to 83% at 30 and 60 years, respectively. Affected patients showed high clinical variability, ranging from monolateral to bilateral glomus tumours variably associated or not with paragangliomas or phaeochromocytomas. Loss of heterozygosity was observed in tumour cells isolated by laser capture microdissection.
CONCLUSIONS: This study shows that a single founder SDHD mutation is present in an area of central Italy and that this mutation is associated with widely variable interfamilial and intrafamilial expressivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061558      PMCID: PMC1736123          DOI: 10.1136/jmg.2004.030353

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  12 in total

Review 1.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

2.  Diagnosis and management of hereditary paraganglioma syndrome due to the F933>X67 SDHD mutation.

Authors:  Monica L Marvin; Carol R Bradford; James C Sisson; Stephen B Gruber
Journal:  Head Neck       Date:  2009-05       Impact factor: 3.147

3.  Impact of screening kindreds for SDHD p.Cys11X as a common mutation associated with paraganglioma syndrome type 1.

Authors:  Mariola Peczkowska; Zoran Erlic; Michael M Hoffmann; Mariusz Furmanek; Jaroslaw Cwikla; Agata Kubaszek; Aleksander Prejbisz; Zbigniew Szutkowski; Andrzej Kawecki; Krzysztof Chojnowski; Anna Lewczuk; Mieczyslaw Litwin; Witold Szyfter; Martin A Walter; Maren Sullivan; Charis Eng; Andrzej Januszewicz; Hartmut P H Neumann
Journal:  J Clin Endocrinol Metab       Date:  2008-09-30       Impact factor: 5.958

4.  Genetic screening for pheochromocytoma: should SDHC gene analysis be included?

Authors:  M Mannelli; T Ercolino; V Giachè; L Simi; C Cirami; G Parenti
Journal:  J Med Genet       Date:  2007-06-08       Impact factor: 6.318

5.  Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation.

Authors:  Elena Rapizzi; Tonino Ercolino; Rossella Fucci; Benedetta Zampetti; Roberta Felici; Daniele Guasti; Andrea Morandi; Elisa Giannoni; Valentino Giaché; Daniele Bani; Alberto Chiarugi; Massimo Mannelli
Journal:  Horm Cancer       Date:  2014-03-05       Impact factor: 3.869

6.  Malignant extra-adrenal pheochromocytoma caused by an SDHB intronic variation leading to a 54-bp deletion in exon 4.

Authors:  T Ercolino; C Taurino; R Sestini; A V Bacca; M Genuardi; M Mannelli; G P Bernini
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

Review 7.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.

Authors:  B Pasini; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

8.  Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas.

Authors:  Valeria Ramundo; Tonino Ercolino; Antongiulio Faggiano; Valentino Giachè; Benedetta Ragghianti; Elena Rapizzi; Annamaria Colao; Massimo Mannelli
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-18       Impact factor: 5.555

9.  The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency.

Authors:  Jean-Pierre Bayley; Peter Devilee; Peter E M Taschner
Journal:  BMC Med Genet       Date:  2005-11-16       Impact factor: 2.103

Review 10.  Paragangliomas/Pheochromocytomas: clinically oriented genetic testing.

Authors:  Rute Martins; Maria João Bugalho
Journal:  Int J Endocrinol       Date:  2014-05-12       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.